Highest-materiality recent filing
Fulcrum cuts workforce 85% after SCD drug failure; hires Leerink for strategic review
Workforce reduced from 57 to 9 employees (~85% cut) after discontinuing pociredir for sickle cell disease.
Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review
Discontinued pociredir for sickle cell disease after FDA feedback; no viable regulatory path forward.
CFO Alan Musso retiring; will stay until successor named then consultant through Feb 2027.
Fulcrum Therapeutics Q4/FY2025: positive pociredir Phase 1b HbF data; net loss widens to $74.9M
Positive 12-week pociredir Phase 1b results: mean absolute HbF increased 12.2% (7.1% to 19.3%); improvements in hemolysis, anemia, and VOC trends.
Fulcrum reports ~$352.3M cash as of Dec 31, 2025; updates presentation for JPM conference
Preliminary unaudited cash, cash equivalents and marketable securities of $352.3M as of December 31, 2025.
Fulcrum Therapeutics prices $175M upsized public offering of common stock and pre-funded warrants
Priced underwritten offering of 11,851,853 shares at $13.50/share and pre-funded warrants for 1,111,193 shares at $13.499 each.
Mean absolute HbF increased 9.9% at Week 6 in 20 mg cohort (vs 5.6% in 12 mg); 7 of 12 patients (58%) achieved HbF ≥20%.
Fulcrum Therapeutics Q3 loss $19.6M; pociredir 20mg cohort enrolled, data due year-end
Cash, equivalents and marketable securities $200.6M; cash runway into 2028.
Fulcrum Q2 net loss $17.3M; pociredir Phase 1b shows HbF increase 8.6% in SCD
Q2 2025 net loss $17.3M vs net income $55.4M in Q2 2024; cash $214.1M, runway into 2028.
Fulcrum Q1 net loss $17.7M; pociredir 12mg cohort enrolled, 20mg cohort initiated
Net loss of $17.7M for Q1 2025 vs $26.9M in Q1 2024; cash $226.6M at March 31, 2025.
MyoKardia terminates Fulcrum collaboration; Fulcrum loses future milestones and royalties
MyoKardia (BMS unit) terminated the collaboration agreement for convenience; effective June 26, 2025.
Fulcrum Therapeutics reports Q4 2024 net loss $16.6M; cash $241M, runway into at least 2027
Full-year 2024 net loss $9.7M vs $97.3M in 2023, driven by $80M Sanofi upfront payment.
Sanofi terminates losmapimod deal; Fulcrum loses up to $975M in milestones
Sanofi terminated for convenience the May 2024 collaboration for losmapimod (FSHD) effective April 17, 2025.
Fulcrum Therapeutics Q3 net loss $21.7M, cash $257.2M; losmapimod halted, PIONEER trial ongoing
Net loss $21.7M in Q3 2024 vs $24.0M loss in Q3 2023; R&D expenses down to $14.6M from $18.2M.
Fulcrum Therapeutics reduces workforce from 80 to 51, expects $10M annual savings
Workforce reduction of 29 employees (36%) to focus on pociredir, DBA, and early discovery; suspends losmapimod.
Fulcrum Therapeutics Phase 3 losmapimod trial fails; program suspended
REACH trial missed primary endpoint: RSA change p=0.75 vs placebo at week 48.
RA Capital exchanged 8,500,000 shares for a pre-funded warrant for 8,500,000 shares at $0.001 exercise price, no expiration.
Fulcrum Therapeutics reports Q2 net income of $55.4M, on track for Phase 3 FSHD data by Oct 2024
Net income $55.4M vs net loss $23.8M in Q2 2023; revenue $80M from Sanofi upfront payment.
Fulcrum signs $80M upfront Sanofi deal for losmapimod ex-U.S.; Q1 net loss $26.9M
Sanofi pays $80M upfront; Fulcrum eligible for up to $975M in milestones and tiered low-teens to mid-twenties royalties on ex-U.S. sales.
On November 12, 2024, the Board, upon the recommendation from the Nominating and Corporate Governance Committee, appointed Rachel King as a member of the Board, with immediate effect to fill the vacancy created by Dr. Collins' resignation.
On November 12, 2024, James J. Collins, a Class II director, notified the board of directors, or the Board, of Fulcrum Therapeutics, Inc., or Fulcrum, of his decision to resign as a member of the Board and all committees thereof, with immediate effect.
elected Colin Hill as a member of the Board, effective June 17, 2024
Max materiality 0.90 · Median 0.68 · Most common event other_material